On the international market, the diabetes medicines are available at relatively low costs; for example, the median monthly treatment costs in 2015 were US$ 0.50 for gliclazide 80 mg, US$ 1.94 for metformin, and US$ 4.35 for regular or neutral protamine Hagedorn insulin (WHO Collaborating Centre for Drug Statistics Methodology, 2018). Here, INS is linked to diabetes mellitus.